Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs publication / By David Žihala
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials publication / By David Žihala
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment publication / By David Žihala
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies publication / By David Žihala
OMIP-117: 40-Parameter/37-Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients publication / By David Žihala
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma publication / By David Žihala
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis publication / By David Žihala
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential publication / By David Žihala
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma publication / By Serafim Nenarokov
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignancies publication / By Serafim Nenarokov
